ArticleArthritis research & therapy2026
Development and validation of a risk score for serious infection in patients with rheumatic diseases receiving prolonged high-dose glucocorticoids.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough previous studies have demonstrated that high-dose glucocorticoids (GCs) significantly increase the risk of infection in patients with autoimmune inflammatory rheumatic diseases (AIRDs), the actual risk for individual patients varies depending on other clinical factors. This study aimed to develop and validate a scoring system for identifying patients at high risk of serious infection following high-dose GC treatment for AIRDs.
methodsPatients with AIRDs treated with prolonged (≥ 4 weeks) high-dose GCs (≥ 30 mg/day prednisone) were included from two referral hospitals. Primary outcome was 1-year incidence of serious infection. Cox regression with LASSO regularization was applied to select covariates for the final model from 19 prespecified factors. A scoring system was developed based on β-coefficients of covariates in the final model.
resultsIn the derivation cohort (n = 1635), serious infection occurred in 153 patients, with an incidence rate (per 100 person-years) of 10.5 (95% CI 9.0–12.3). The LASSO regularization identified older age, interstitial lung disease, decreased renal function, anemia, low serum albumin, ANCA-associated vasculitis, and concomitant rituximab and cyclophosphamide as key risk factors. The resulting scoring system, termed the CORAL score (0–20), demonstrated good predictive performance (AUROC 0.726 [95% CI 0.681–0.771]) for serious infections. Based on the score, patients were stratified into low- (score ≤ 6) or high-risk group (score > 6). Patients in the high-risk group (n = 343) had significantly higher rates of serious infection (HR 4.85 [3.53–6.67]) and all-cause mortality (HR 4.55 [2.91–7.11]) than those in the low-risk group. The predictive accuracy of the CORAL score was consistent in the external validation cohort (n = 672).
conclusionIn patients with AIRDs receiving prolonged high-dose glucocorticoids, the CORAL score successfully identified those at high risk of serious infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.